Aquinox Pharmaceuticals to Announce 2016 Year End Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
85
Aquinox Pharmaceuticals to Announce 2016 Year End Financial Results

VANCOUVER, British Columbia, March 02, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“ Aquinox ”) (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, will report its financial results for the year ending December 31, 2016 and will provide a general business update on Thursday, March 9, 2017 after U.S. financial markets close. Aquinox will host a conference call and live audio webcast on Thursday, March 9th, 2017 at 4:30 PM (ET) / 1:30 PM (PT).

Conference Call and Webcast Details: Date: Thursday, March 9th, 2017 Time: 4:30 PM (ET) / 1:30 PM (PT) Toll-free: (866) 357-7878 International: (315) 625-3088 Conference ID: 72144360 Webcast URL: http://edge.media-server.com/m/p/askid88w

The live webcast may be accessed through the " Events & Presentations " page in the " Investor Relations " section of the company's website at www.aqxpharma.com .

The archived webcast will also be available on Aquinox 's website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About Aquinox Pharmaceuticals, Inc.

Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing.  In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS).  Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com .

Investor Contact Info:

Brendan Payne Associate Director, Investor Relations Aquinox Pharmaceuticals, Inc. 604.901.3019 ir@aqxpharma.com

Gitanjali Ogawa Vice President The Trout Group 646-378-2949 Gogawa@troutgroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fermi's Leadership Saga: Proxy Wars and Power Struggles

Updated Category News Views 61

Unfolding the Drama at Fermi (NASDAQ:FRMI) You'd think you were watching a suspense drama unfold, not an annual shareholder meeting report. The co-founder of Fermi, Toby Neugebauer, stepped into the spotlight, throwing shade at Rick Perry and the board's shaky status quo. Pitting Shareholders Against the Board Neugebauer isn't mincing words about the current state of...

Continue Reading
Senstar Boasts Robust Q3 Growth Amid Global Demand

Updated Category News Views 83

A Standout Quarter for Senstar Technologies How often do you see a company jumping 37% in revenue year-over-year? Not every day, that’s for sure. But that's exactly what's happening with Senstar Technologies Corporation (NASDAQ: SNT). For the third quarter of 2026, they've pulled in $13.1 million compared to last year’s $9.5 million. And that's not just some fluke –...

Continue Reading
Research Solutions Set to Reveal Q1 FY27 Results

Updated Category News Views 89

Understanding the Stakes Ahead of RSSS's Earnings Call Aw, the sweet suspense of earnings season. Research Solutions, Inc. (NASDAQ: RSSS) has circled November 12, 2026, as the date to let investors in on its numbers for the first quarter of fiscal year 2027. A date that's gotta have the folks over at RSSS feeling like it’s judgment day. You know how it goes—market...

Continue Reading
Key Life Events That Demand a Financial Plan Change

Updated Category News Views 49

Navigating Life's Milestones with Financial Savvy Nothing stirs the financial pot quite like life's big events. The grind of daily life might trick you into thinking everything's fine, but ignore these milestones at your peril. Ted Thatcher, a financial advisor from Roseville, California, lays it out in HelloNation's latest foray into sound financial planning: your...

Continue Reading
Encompass Health Faces Uncertain Future with Sea Pines

Updated Category News Views 55

Unexpected Downpour Closes Sea Pines They say when it rains, it pours. That's not just true in life, but as it happens, it's quite literal in Melbourne, Florida. A deluge of biblical proportions forced an immediate lockdown of the Sea Pines Rehabilitation Hospital. Flooded to the gills, this once stalwart institution finds its doors shuttered indefinitely. It's a...

Continue Reading
Array Digital's Q3 2026 Earnings: Strategic Wins and Challenges

Updated Category News Views 36

From Towers to Earnings: Array Digital's 2026 Path Array Digital Infrastructure, Inc. (NYSE:AD) just rolled out its Q3 2026 numbers, and honestly, it's a mixed bag. This company is one of those handy barometers for the telecom infrastructure market, especially now that it's a full-blown tower company. They've pitched an earnings call for the early birds at 9 a.m. CT...

Continue Reading
Deep Principle's Hydrogen-1.0: A Leap in AI-Driven Chemistry

Updated Category News Views 101

Leaving Old Lab Notebooks in the Dust Deep Principle just shook up the science lab with their latest brainchild, Hydrogen-1.0. We're talking about an AI-driven marvel designed to tackle chemistry and materials research like no traditional lab rat ever could. On November 4, they rolled out this bad boy—an open-weight model fine-tuned to turn vague scientific hunches into...

Continue Reading
S&P 500 Drop: A Market Glitch or Future Trend?

Updated Category News Views 34

A Sudden Jolt in a Trending Market Mornings like these make you question your coffee strength. A major market dip, with the S&P 500 shedding 3.51%, is like a slap to the face, especially when the Nasdaq Composite takes a 5.24% nosedive. The Dow isn't spared, dropping 2.45%. But, let's not lose our heads here. Today is a blip, a pixel in the bigger picture where the S&P...

Continue Reading
UP Fintech Faces 25% Stock Drop Amid Fraud Suit

Updated Category News Views 67

Stock Market Whiplash: UP Fintech's Rough Ride You know, just when you think you've seen it all in this bonkers stock market world, something like a 25% drop in UP Fintech’s stock reminds you that surprises never end. Now, UP Fintech’s facing a class action lawsuit, alleging it didn’t exactly play fair, sparking this latest rollercoaster ride. Yeah, buckle up folks,...

Continue Reading
Gildan Class Action: What Investors Should Know

Updated Category News Views 9

Playing Hardball: Gildan Faces Serious Claims Gildan Activewear Inc. (NYSE:GIL) isn't just dealing with wardrobe malfunctions; it's knee-deep in a class action lawsuit that's got investors on edge. The allegations? Accusations of deceptive practices like channel stuffing, which supposedly jazzed up their financials by moving unsold products through distribution channels...

Continue Reading

Top 5 Most Recently Viewed Articles

Americas CarMart Sees Director Buy Shares Amid Company Changes

Updated Category News Views 124

Director's Stock Purchase at Americas CarMart Americas CarMart Inc. (NASDAQ: CRMT) has recently caught the public's attention as director Ann G. Bordelon purchased shares worth $52,976. This acquisition signals a strong confidence in the used car dealership's ability to face the competitive market and continue on its path toward growth and success. The Acquisition Details...

Continue Reading
Scully Royalty Reports Half-Year Results and announces Dividend

Updated Category News Views 94

Scully Royalty Ltd. Half-Year Financial Report Insights Scully Royalty Ltd. (NYSE: SRL) has recently published its half-year report, detailing its financial results for the six months concluded. The report, referred to as the Half-Year Report, reflects the company's business performance and strategic updates. Dividend Declaration and Financial Performance In conjunction...

Continue Reading
Inozyme Pharma's 2024 Financial Update and Future Focus

Updated Category News Views 154

Inozyme Pharma's Strategic Vision for 2024 Inozyme Pharma, Inc. (NASDAQ: INZY) is making significant strides as it navigates the dynamic landscape of biotechnology. The company specializes in developing breakthrough therapeutics tailored for rare diseases impacting bone health and vascular function. As of December 31, 2024, Inozyme announced its financial results...

Continue Reading
Strategy Inc Partners with Snowflake for AI Data Solutions

Updated Category News Views 245

Strategy Inc and Snowflake Team Up for Enhanced Data Management Strategy Inc (NASDAQ: MSTR) has announced its partnership with Snowflake Inc (NYSE: SNOW) to establish a more standardized framework for managing data effectively. This collaboration aims to simplify and streamline the data landscape through the Open Semantic Interchange (OSI) Advancing Open Data Standards As...

Continue Reading
Innovative Industrial Properties Faces Legal Challenges Ahead

Updated Category News Views 129

Innovative Industrial Properties Legal Challenges Shareholders of Innovative Industrial Properties, Inc. (NYSE: IIPR) are currently navigating a troubling period as the company faces a lawsuit for securities law violations. This situation raises important questions for investors who may be affected. Class Period and Allegations The allegations against IIPR highlight...

Continue Reading